PD44-02 PHARMACOGENOMIC DETERMINANTS OF SERUM STEROID HORMONE RESPONSES TO ABIRATERONE OR ENZALUTAMIDE AND HSD3B1 GENE MUTATION IN CRPC PATIENTS

You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology II (PD44)1 Sep 2021PD44-02 PHARMACOGENOMIC DETERMINANTS OF SERUM STEROID HORMONE RESPONSES TO ABIRATERONE OR ENZALUTAMIDE AND HSD3B1 GENE MUTATION IN CRPC PATIENTS Hosam Serag, Emilia Chen, Hans Adomat, Daniel Khalaf, Alexander Wyatt, and Martin Gleave SeragHosam Serag More articles by this author , ChenEmilia Chen AdomatHans Adomat KhalafDaniel Khalaf WyattAlexander Wyatt GleaveMartin View All Author Informationhttps://doi.org/10.1097/JU.0000000000002058.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION OBJECTIVE: Abiraterone enzalutamide are commonly used for treating patients with castration-resistant prostate cancer (CRPC). Serum levels steroid hormones can be affected drug type mutation in the gene HSD3B1, potential implications outcome prediction. Objective: To determine impact treatment abiraterone or as well on hormones, quantified mass spectrometry (MS) CRPC. METHODS: A multicentre, randomised, crossover trial was performed six centres British Columbia, Canada. Adult metastatic were included. In study we retrospective MS analysis from both arms trial.Patients randomly assigned groups B (1:1). Group received acetate until PSA progression, followed Enzalutamide. opposite sequence. Primary outcomes included testosterone (T), dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), androstenedione, progesterone at baseline, before crossover, end therapy (EOT) variants allele. RESULTS: Baseline serum T, DHT, DHEA, similar between two arms. On androstenedione significantly decreased, while level increased, arm compared arm. This is reversed after patient cross-over (Figure 1). No significant association detected (1245 A) A>C) genotypes either exposure 2). The sample size relatively small assessing effect mutations. CONCLUSIONS: results confirm expected effects patients. seems not affect hormones. Source Funding: None © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e736-e737 Advertisement Copyright Permissions© Inc.MetricsAuthor Information Expand Loading ...